Johnson & Johnson’s Earnings Are Coming. They’ll Be the First Since the Kenvue Spinoff.

• Johnson & Johnson will report its quarterly financial results without the results of its consumer health division for the first time.
• Analysts expect earnings of $2.52 per share and sales of $21 billion for the third quarter.
• Investors will be looking for updates on the litigation over Johnson & Johnson’s talc products.
• Updates on growth prospects for Johnson & Johnson’s drug business and the impact of GLP-1 obesity drugs on the medical device business will also be of interest.
• Johnson & Johnson shares are down more than 10% this year.

When Johnson & Johnson reports its quarterly financial results, it will be the first time without the consumer health division. Analysts expect earnings of $2.52 per share and sales of $21 billion. The litigation over talc products remains a key issue. Updates on growth prospects for the drug business and the impact of obesity drugs on the medical device business will also be of interest. Johnson & Johnson shares have declined more than 10% this year.